ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > stupid price

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Dec 11, 2021 11:11am

117 Views

Post# 34221616

RE:RE:RE:stupid price

Congrats on the 12c average.
I would've been closer to 12 myself if I hadn't bought progressively as the stock was plummeting from 20 to 17. Mistakenly thought we would never see these prices again, learnt my lesson, but hey who knows, it can go lower after a Nasdaq listing. Look what happened to Acumen. 1/3 of its listing price.

it's definitely gonna be a roller coaster ride over the next 24 months....got to have a stomachache for it.

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs